作者: Marino Venerito , Peter Malfertheiner
DOI: 10.1111/J.1523-5378.2010.00762.X
关键词: In patient 、 Duodenal cancer 、 Helicobacter pylori infection 、 Anti-inflammatory 、 Medicine 、 Internal medicine 、 Helicobacter pylori 、 Pharmacotherapy 、 Nonsteroidal 、 Gastroenterology 、 Randomized controlled trial
摘要: Background: Gastric (GU) and duodenal ulcers (DU) are in most instances either induced by Helicobacter pylori infection or nonsteroidal anti-inflammatory drugs (NSAIDs). Whether eradication of H. is beneficial NSAID users for preventing GU DU has been the focus different studies. Materials Methods: Mechanisms shared both NSAIDs induction were reviewed randomized controlled trials on prevention healing patients requiring therapy identified a PubMed search. Results: Key factors decrease pH, imbalance between apoptosis proliferation, reduction mucosal blood flow, recruitment polymorphonucleates distinct compartments. For primary ulcer prevention, before starting an reduces risk virtually abolishes DU. alone not sufficient secondary appears to further increase protective effects proton-pump inhibitors (PPI) reduce relapse. does influence if intake discontinued. Conclusions: Duodenal more closely related than users. recommended therapy. PPI mandatory gastroduodenal ulcers, relapse presence pylori.